Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Rises By 137.6%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 868,800 shares, an increase of 137.6% from the March 15th total of 365,600 shares. Based on an average daily trading volume, of 376,700 shares, the short-interest ratio is currently 2.3 days.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS opened at $1.04 on Thursday. The firm’s 50 day moving average price is $0.86 and its 200-day moving average price is $0.75. The company has a market cap of $78.70 million, a PE ratio of -0.65 and a beta of 2.34. Aligos Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.38.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Tuesday, March 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.05. The firm had revenue of $2.68 million for the quarter, compared to the consensus estimate of $3.20 million. Aligos Therapeutics had a negative net margin of 607.03% and a negative return on equity of 116.41%. On average, analysts forecast that Aligos Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Newtyn Management LLC raised its holdings in shares of Aligos Therapeutics by 2.2% during the third quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock valued at $687,000 after purchasing an additional 20,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Aligos Therapeutics by 5.0% during the fourth quarter. Geode Capital Management LLC now owns 199,858 shares of the company’s stock valued at $190,000 after purchasing an additional 9,440 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Aligos Therapeutics during the first quarter valued at approximately $94,000. Mirabella Financial Services LLP purchased a new position in shares of Aligos Therapeutics during the first quarter valued at approximately $88,000. Finally, State Street Corp raised its holdings in shares of Aligos Therapeutics by 60.2% during the first quarter. State Street Corp now owns 97,423 shares of the company’s stock valued at $85,000 after purchasing an additional 36,600 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).